Original Publication Date: 1 January, 2017
Publication / Source: Nanomedicine
Authors: Michael R King & Zeinab J Mohamed
Current cancer therapies aim to reverse tumorigenesis through nonspecific elimination of cancer cells within the body, which can often result in systemic side effects for patients. Nanoparticles provide a unique platform for cancer therapeutics because their physical properties can be tailored to target-specific cancers, increase the bioavailability and accumulation of drugs, and reduce systemic effects of current therapies [1,2]. In recent years, nanoparticles for the treatment of cancer cells have evolved beyond a single delivery system to a realm of dual-loaded delivery of cancer therapeutics.